ArticleJACC. Advances2023
Article in JACC. Advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Pooled it
- Three vs 12-month DAPT after implantation of biodegradable-polymer sirolimus-eluting coronary stent: a randomised clinical trial.BMC medicine · 2025Trial
- CYP450 Metabolizer Phenotypes in a Turkish Emergency Cardiac Patient Cohort: A Descriptive Pharmacogenomic Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Inclusion of older adults in UK clinical research-the National Institute for Health and Care Research Year of Birth Project.Age and ageing · 2026Article
- Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature.Clinical and translational science · 2026Review
- The OurHealth Study: A digital genomic cohort for cardiometabolic risk mechanisms in US South Asians.NPJ digital medicine · 2026Review
- Evidence-biased medicine? Applying a health equity lens to Sackett's methodological framework.The British journal of general practice : the journal of the Royal College of General Practitioners · 2025Article
- Family health history and pharmacogenomics show cross generation premature amitriptyline discontinuation is associated with CYP2C19 loss of-function enrichment.Communications medicine · 2025Article
- CYP2C19 Polymorphism and Clopidogrel Efficacy in Long-Term Outcomes of Large-Artery Atherosclerotic Stroke: The NCVC Genome Registry.JACC. Asia · 2025Article
- Article
- Integrative pharmacogenomics analysis predicts the platelet response in clopidogrel treated coronary artery disease (CAD) patients of South India.Scientific reports · 2025Article
- Embedding Pharmacogenetics Into Clinical Practice to Improve Patient Outcomes.Annals of human genetics · 2025Review
- Clinician Experiences at the Frontier of Pharmacogenomics and Future Directions.Journal of personalized medicine · 2025Article
- The clinical and molecular landscape of breast cancer in women of African and South Asian ancestry.Nature communications · 2025Article
- Embedding equity, diversity and inclusion processes within clinical trials and health and social care research.BMJ open · 2025Review
- Association ofBalkan journal of medical genetics : BJMG · 2024Article
- Effects of treatment with clopidogrel with or without proton pump inhibitor omeprazole on the risk of ischemic stroke: a nationwide cohort study.Scientific reports · 2024Article
- CYP2C19 Poor Metabolizer Status and High System Inflammation Response Index are Independent Risk Factors for Premature Myocardial Infarction: A Hospital-Based Retrospective Study.International journal of general medicine · 2024Article
- A review of clopidogrel resistance in lower extremity arterial disease.JVS-vascular insights · 2024Review
- Factor V Leiden, estrogen, and multimorbidity association with venous thromboembolism in a British-South Asian cohort.iScience · 2023Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Background: Cytochrome P450 family 2 subfamily C member 19 (CYP2C19) is a hepatic enzyme involved in the metabolism of clopidogrel from a prodrug to its active metabolite. Prior studies of genetic polymorphisms in Objectives: The objective of this study was to assess prevalence of common Methods: The Genes & Health cohort of British Bangladeshi and Pakistani ancestry participants were studied. Results: Genes & Health cohort participants (N = 44,396) have a high prevalence (57%) of intermediate or poor CYP2C19 metabolizers, with at least 1 loss-of-function Conclusions: A pharmacogenomic-driven approach to clopidogrel prescribing has the potential to impact significantly on clinical management and outcomes in individuals of Bangladeshi and Pakistani ancestry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.